» Articles » PMID: 35018092

Ocular and Systemic Complications of COVID-19: Impact on Patients and Healthcare

Overview
Journal Clin Ophthalmol
Publisher Dove Medical Press
Specialty Ophthalmology
Date 2022 Jan 12
PMID 35018092
Authors
Affiliations
Soon will be listed here.
Abstract

There is increasing information available about the effects of the SARS-CoV-2 virus on the systemic and ocular health of patients, as well as the effects of delayed health care. This mini-review summarizes the potential complications and treatments of COVID-19. Systemic findings include respiratory illness, risk of thromboembolic events, and neurologic findings. Some patients may develop persistent symptoms even after the infection resolves. Effective treatment options include glucocorticoids, antivirals, interleukin-6 antagonists, monoclonal antibodies, Janus kinase inhibitors and vaccines. Potential ocular findings of COVID-19 include conjunctivitis, cranial nerve palsies, and microvascular changes in the retina; most symptoms resolved over time. During the lockdown periods, teleophthalmology was utilized to triage non-urgent issues; patients who did present to emergency departments tended to have more severe disease with worse visual prognoses. While transient delays in outpatient ophthalmic care may be tolerated in some patients, others experienced significant vision loss with interruptions in treatments. Resumption of ophthalmic care as soon as possible may help mitigate the effects of delayed care due to the pandemic.

Citing Articles

Monoclonal Antibodies for the Treatment of Ocular Diseases.

Henriques C, da Ana R, Krambeck K, Miguel S, Santini A, Zielinska A J Clin Med. 2024; 13(19).

PMID: 39407875 PMC: 11482488. DOI: 10.3390/jcm13195815.


Retinal and Corneal OCT Results of Patients Hospitalized and Treated in the Acute Phase of COVID-19.

Wylegala E, Prus-Ludwig A, Mocek P, Tomczyk T, Dugiello B, Madej A J Clin Med. 2024; 13(18).

PMID: 39337050 PMC: 11432357. DOI: 10.3390/jcm13185564.


The Implications of SARS-CoV-2 Infection in a Series of Neuro-Ophthalmological Manifestations-Case Series and Literature Review.

Anton N, Bogdanici C, Branisteanu D, Ilie O, Pavel I, Doroftei B J Clin Med. 2023; 12(11).

PMID: 37297989 PMC: 10253682. DOI: 10.3390/jcm12113795.


Case of acute vision loss after injectable remdesivir with anticoagulants and overdose of antibiotics: A late report.

Mitra S Indian J Ophthalmol. 2023; 71(5):2275-2279.

PMID: 37202970 PMC: 10391412. DOI: 10.4103/ijo.IJO_1580_22.


Genome-Wide Pleiotropy Study Identifies Association of with Age-Related Macular Degeneration and COVID-19 Infection Outcomes.

Chung J, Vig V, Sun X, Han X, OConnor G, Chen X J Clin Med. 2023; 12(1).

PMID: 36614910 PMC: 9821609. DOI: 10.3390/jcm12010109.


References
1.
Cai R, Novosad P, Tandel V, Asher S, Malani A . Representative estimates of COVID-19 infection fatality rates from four locations in India: cross-sectional study. BMJ Open. 2021; 11(10):e050920. PMC: 8493602. DOI: 10.1136/bmjopen-2021-050920. View

2.
Cavuoto K, Vanner E, Osigian C . Trends in pediatric ocular trauma presenting to an ophthalmology-specific emergency department during the COVID-19 pandemic. J AAPOS. 2021; 25(3):170-172. DOI: 10.1016/j.jaapos.2021.01.004. View

3.
ElMohsen M, Youssef M, Mamdouh Esmat S, Teleb D, Tolba D . Consequences of COVID-19 on Uveitis Patients from Their Own Perspective: A Questionnaire-based Study. Ocul Immunol Inflamm. 2021; 30(7-8):1842-1847. DOI: 10.1080/09273948.2021.1964029. View

4.
Goligher E, Bradbury C, McVerry B, Lawler P, Berger J, Gong M . Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. N Engl J Med. 2021; 385(9):777-789. PMC: 8362592. DOI: 10.1056/NEJMoa2103417. View

5.
Ma N, Li P, Wang X, Yu Y, Tan X, Chen P . Ocular Manifestations and Clinical Characteristics of Children With Laboratory-Confirmed COVID-19 in Wuhan, China. JAMA Ophthalmol. 2020; 138(10):1079-1086. PMC: 7450405. DOI: 10.1001/jamaophthalmol.2020.3690. View